BioHedge Weekly
13D/13G filings from 18 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform with clinical trials, SEC filings, and hedge fund positioning, linked by company.
Weekly Delivery
Get next week's BioHedge Weekly by email
One email per week. We follow up on coverage that's relevant to you.
or email [email protected]
Weekly Filing Volume
Filings This Week
| Fund / Company | Ownership & Type |
|---|---|
Deerfield Management BiomX Inc. (PHGE) | 8.1% -1.9 13D/A [SEC] |
BVF Partners L.P. | 5.3% New 13G [SEC] |
Baker Brothers Advisors Kiniksa Pharmaceuticals International, plc (KNSA)
Investment
Other | 7.0% 13D/A [SEC] Baker Brothers Advisors, on behalf of its funds, entered into a Deed of Waiver with Kiniksa Pharmaceuticals International, plc, irrevocably waiving their right to convert Class A1 and Class B1 ordinary shares into Class A or Class B ordinary shares if such conversion would result in the funds beneficially owning more than 49.9% of the outstanding voting rights in the Issuer. The funds hold securities for investment purposes and may adjust their holdings based on various market and business factors. Agreements · Baker Brothers Advisors, on behalf of its funds, entered into a Deed of Waiver with Kiniksa Pharmaceuticals International, plc, waiving the funds' right to convert Class A1 and Class B1 ordinary shares if it would lead to them owning more than 49.9% of the Issuer's voting rights. The Issuer agreed not to effect conversions circumventing this waiver, and the funds agreed not to transfer these shares to affiliates unless the transferee adheres to similar restrictions. |
New Positions
Funds disclosing more than 5% ownership in a company for the first time.
| Fund / Company | Ownership & Type |
|---|---|
BVF Partners L.P. | 5.3% SC 13G [SEC] |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses more than 5% ownership in a company for the first time.
We track 18 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.